Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor
A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer
Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients
Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy
A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy
Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s
A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
